Ken Griffin Beam Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $700,260 - $1.08 Million	33,000 Added 67.48%	81,900 $1.92 Million
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $260,406 - $500,277	-11,100 Reduced 18.5%	48,900 $1.62 Million
Q4 2023 Feb 14, 2024	SELL	$17.69 - $30.76 $1.37 Million - $2.39 Million	-77,600 Reduced 56.4%	60,000 $1.63 Million
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $2.54 Million - $3.58 Million	110,200 Added 402.19%	137,600 $3.31 Million
Q2 2023 Aug 14, 2023	SELL	$29.32 - $35.99 $1.16 Million - $1.42 Million	-39,400 Reduced 58.98%	27,400 $874,000
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $198,990 - $322,014	6,600 Added 10.96%	66,800 $2.05 Million
Q4 2022 Feb 14, 2023	SELL	$36.73 - $51.6 $5.41 Million - $7.61 Million	-147,400 Reduced 71.0%	60,200 $2.35 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $5.28 Million - $9.34 Million	132,800 Added 177.54%	207,600 $9.89 Million

230

73.3M

283K

233K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.84B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.